{
    "clinical_study": {
        "@rank": "15124", 
        "arm_group": [
            {
                "arm_group_label": "Levofloxacin and Streptomycin added", 
                "arm_group_type": "Experimental", 
                "description": "Levofloxacin and Streptomycin added : Cycloserine(CS) 250mg bid, P-aminosalicylic acid(PAS) 2 pack bid, Prothionamide(PTH) 250mg (125mg x 2 tab) bid, Pyrazinamide(PZA) 1500mg (500mg x 3 tab) qd, Levofloxacin 750mg (500mg x 1.5 tab) qd, Streptomycin 1g IM qd"
            }, 
            {
                "arm_group_label": "Moxifloxacin and Kanamycin added", 
                "arm_group_type": "Experimental", 
                "description": "Cycloserine(CS) 250mg bid, P-aminosalicylic acid(PAS) 2 pack bid, Prothionamide(PTH) 250mg (125mg x 2 tab) bid, Pyrazinamide(PZA) 1500mg (500mg x 3 tab) qd, Moxifloxacin 400mg (400mg x 1 tab) qd, Kanamycin 1g IM qd"
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to investigate the pharmacokinetic characteristics of second-line\n      anti-tuberculosis agents after oral/intramuscular administration in healthy male volunteers."
        }, 
        "brief_title": "Clinical Trial to Investigate the Pharmacokinetics of Second-Line Anti-Tuberculosis Agents", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "condition_browse": {
            "mesh_term": "Tuberculosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  healthy male subject aged 20 to 50 at screening\n\n          -  a body weight in the range of 55 kg (inclusive) to 90 kg (inclusive) with ideal body\n             weight range of 19.0 to 26.0 subjects who decide to participate voluntarily and write\n             a informed consent form\n\n        Exclusion Criteria:\n\n          -  subjects who have clinically significant disease of cardiovascular, respiratory,\n             renal, endocrinological, hematological, gastrointestinal, neurological(central\n             nervous system), psychiatric disorders or malignant tumor\n\n          -  subject judged not eligible for study participation by investigator."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02128308", 
            "org_study_id": "TBPK"
        }, 
        "intervention": [
            {
                "arm_group_label": "Levofloxacin and Streptomycin added", 
                "intervention_name": "Levofloxacin and Streptomycin added", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Cycloserine", 
                    "P-aminosalicylic acid", 
                    "Prothionamide", 
                    "Pyrazinamide", 
                    "levofloxacin", 
                    "steptomycin"
                ]
            }, 
            {
                "arm_group_label": "Moxifloxacin and Kanamycin added", 
                "intervention_name": "Moxifloxacin and Kanamycin added", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Cycloserine", 
                    "P-aminosalicylic acid", 
                    "Prothionamide", 
                    "Pyrazinamide", 
                    "moxifloxacin", 
                    "kanamycin"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aminosalicylic Acid", 
                "Antitubercular Agents", 
                "Cycloserine", 
                "Prothionamide", 
                "Pyrazinamide", 
                "Kanamycin", 
                "Ofloxacin", 
                "Streptomycin", 
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Antituberculosis agents", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "April 29, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul National University Bundang Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Open-label, Single Sequence Clinical Trial to Investigate the Pharmacokinetic Characteristics of Second-Line Anti-Tuberculosis Agents After Multiple Oral/Intramuscular Administration in Healthy Male Volunteers", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Ministry for Health, Welfare and Family Affairs", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "AUC (Area under the plasma concentration versus time curve), Cmax(maximum plasma concentration)", 
            "measure": "AUC (area under the plasma concentration-time curve)", 
            "safety_issue": "No", 
            "time_frame": "Predose and 2d 0h, 3d 0h, 4d 0h, and 5d 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24h postdose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02128308"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Bundang Hospital", 
            "investigator_full_name": "Jae Yong Chung", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}